BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10442193)

  • 1. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.
    Briasoulis E; Karavasilis V; Anastasopoulos D; Tzamakou E; Fountzilas G; Rammou D; Kostadima V; Pavlidis N
    Ann Oncol; 1999 Jun; 10(6):701-6. PubMed ID: 10442193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
    Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
    J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
    Kouroussis C; Agelaki S; Mavroudis D; Souglakos J; Kakolyris S; Kalbakis K; Vardakis N; Reppa D; Hatzidaki D; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2000; 46(6):488-92. PubMed ID: 11138462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I-II parallel study of docetaxel on a bimonthly schedule in refractory metastatic breast carcinoma.
    Gebbia V; Borsellino N; Testa A; Tirrito ML; Ferrera P; Colombo A; Mauceri G; Marrazzo A; Porretto F; Musso M
    Breast Cancer Res Treat; 2003 Jan; 77(2):99-108. PubMed ID: 12602908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
    Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly administration of docetaxel (Taxotere): summary of clinical data.
    Hainsworth JD; Burris HA; Greco FA
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):19-24. PubMed ID: 10437747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
    Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
    Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
    Blaney SM; Seibel NL; O'Brien M; Reaman GH; Berg SL; Adamson PC; Poplack DG; Krailo MD; Mosher R; Balis FM
    J Clin Oncol; 1997 Apr; 15(4):1538-43. PubMed ID: 9193350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel (Taxotere) administered in weekly schedules.
    Greco FA
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
    Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
    Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of docetaxel with concomitant thoracic radiation therapy.
    Mauer AM; Masters GA; Haraf DJ; Hoffman PC; Watson SM; Golomb HM; Vokes EE
    J Clin Oncol; 1998 Jan; 16(1):159-64. PubMed ID: 9440738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity.
    Kuroi K; Bando H; Saji S; Toi M
    Breast Cancer; 2003; 10(1):10-4. PubMed ID: 12525757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel administered on a weekly basis for metastatic breast cancer.
    Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
    J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly docetaxel as II line therapy in non-small cell lung cancer: an interim analysis of a phase II study.
    Valerio MR; Russo A; Latteri MA; Modica G; Gulotta G; Armata MG; Bajardi E; Cicero G; Pantuso G; Grassi N; Agosta G; Gebbia N
    Lung Cancer; 2001 Dec; 34 Suppl 4():S31-5. PubMed ID: 11742700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer.
    Hainsworth JD; Vokes EE
    Semin Oncol; 2001 Feb; 28(1 Suppl 2):22-7. PubMed ID: 11284621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.
    ten Bokkel Huinink WW; Prove AM; Piccart M; Steward W; Tursz T; Wanders J; Franklin H; Clavel M; Verweij J; Alakl M
    Ann Oncol; 1994 Jul; 5(6):527-32. PubMed ID: 7918124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
    Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
    Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
    Kreis W; Budman DR; Fetten J; Gonzales AL; Barile B; Vinciguerra V
    Ann Oncol; 1999 Jan; 10(1):33-8. PubMed ID: 10076719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.